High-density lipoproteins and cardiovascular disease: 2010 update

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 3, 2010, Pages 413-423

  Alwaili, Khalid ^a   Awan, Zuheir ^a   Alshahrani, Ali ^a   Genest, Jacques ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Atherosclerosis; Cardiovascular diseases; Cholesterol; High density lipoproteins; Preventive cardiology

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ABC TRANSPORTER A1; ACETYLSALICYLIC ACID; ANACETRAPIB; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLOFIBRATE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPID; PLACEBO; PRAVASTATIN; RO 4607381; SIMVASTATIN; SPHINGOMYELIN PHOSPHODIESTERASE; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DISORDERS OF LIPOPROTEIN METABOLISM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRY SKIN; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; FLUSHING; GASTRITIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART INFARCTION; HEART PROTECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; MUTATIONAL ANALYSIS; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SMOKING CESSATION; THROMBOSIS; VASCULAR ENDOTHELIUM; WEIGHT REDUCTION;

ADULT; AGE DISTRIBUTION; AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; RISK MANAGEMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS;

EID: 77949429915     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.4     Document Type: Review

References (82)

1. Grundy SM, Cleeman JI, Daniels SR et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17), 2735-2752 (2005).
2. Genest J, McPherson R, Frohlich J et al. 2009 Canadian Cardiovascular Society/ Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can. J. Cardiol. 25(10), 567-579 (2009).
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
4. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation 118, 2243-2251 (2008).
5. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30(1), 8-13 (2007).
6. Yusuf S, Hawken S, Ounpuu S et al.; INTERHEART study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438), 937-952 (2004).
7. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ. Res. 95(8), 764-772 (2004).
8. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu. Rev. Med. 54, 321-341 (2003).
9. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ. Res. 98, 1352-1364 (2006).
10. Argraves KM, Gazzolo PJ, Groh EM et al. High density lipoprotein- associated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem. 283, 25074-25081 (2008).
11. Von Eckardstein A, Rohrer L. Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins. Curr. Opin. Lipidol. 20(3), 197-205 (2009).
12. Awan Z, Al Waili K, Alrasadi K, Genest J. Treatment of low high density lipoprotein cholesterol. Can. J. Cardiol. 24, 27c-31c (2008).
13. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50(Suppl.), S189-S194 (2009).
14. Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol. 6(7), 455-463 (2009).
15. Timmins JM, Lee JY, Boudyguina E et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 115(5), 1333-1342 (2005).
16. Brunham LR, Kruit JK, Iqbal J et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116(4), 1052-1062 (2006).
17. Denis M, Haidar B, Marcil M, Krimbou L, Genest J. Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP biding cassette A1 (ABCA1). J. Biol. Chem. 279, 7384-7394 (2004).
18. Haidar B, Denis M, Marcil M, Krimbou L, Genest J. Apolipoprotein A-I activates cellular camp signaling through the ABCA1 receptor. Evidence for molecular interactions between ABCA1 receptor and G protein. J. Biol. Chem. 279, 9963-9969 (2004).
19. Wu Z, Gogonea V, Lee X et al. The double super helix model of high density lipoprotein. J. Biol. Chem. 284(52), 36605-36619 (2009).
20. Vedhachalam C, Duong PT, Nickel M et al. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J. Biol. Chem. 282(34), 25123-25130 (2007).
21. Hassan HH, Denis M, Lee DY et al. Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis. J. Lipid Res. 48(11), 2428-2442 (2007).
22. Hassan HH, Bailey D, Lee DY et al. Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis. J. Biol. Chem. 283(17), 11164-11175 (2008).
23. Bailey D, Ruel I, Hafiane A, Cochrane H et al. Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis. J. Lipid Res. doi:10.1194/jlr. M001875 (2009) (Epub ahead of print).
24. Meigs JB, Wilson PW, Fox CS et al. Body mass index, metabolic syndrome and risk of Type 2 diabetes or cardiovascular disease. J. Clin. Endocrinol. Metab. 91(8), 2906-2912 (2006).
25. Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F. Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. Exp. Gerontol. 44(3), 136-160 (2009).
26. Alrasadi K, Ruel IL, Marcil M, Genest J. Functional mutations in the ABCA1 gene in subjects of French Canadian descent with HDL deficiency. Atheroscler. 188, 281-291 (2006).
27. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305(5685), 869-872 (2004).
28. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest. 114(9), 1343-1353 (2004).
29. Lee C-Y, Vincent J, Lesimple A et al. Increased sphingomyelin content of HDL impairs HDL biogenesis and maturation in human Niemann-Pick disease type B. J. Lipid Res. 47, 322-332 (2006).
30. Lee C-Y, Tamura T, Rabah N et al. The carboxyl-terminal disulfide bond of acid sphingomyelinase is critical to its secretion and enzymatic function. Biochemistry 46(51), 14969-111497 (2007).
31. Dastani Z, Pajukanta P, Marcil M et al. Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French- Canadian subjects. Eur. J. Hum. Genet. 18(3), 342-347 (2009).
32. Iatan I, Dastani Z, Do R et al. Genetic variation at the proprotein convertase subtilisin/kexin type 5 gene modulates HDL cholesterol levels. Circ. Cardiovasc. Genet. 2(5), 467-475 (2009).
33. Martin G, Duez H, Blanquart C et al. Statin-induced inhibition of the r-signaling pathway activates PPARa and induces HDL apoA-I. J. Clin. Invest. 107, 1423-1429 (2001).
34. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study (4S). Lancet 344(8934), 1383-1389 (1994).
35. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009 (1996).
36. No authors listed. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial investigators. N. Engl. J. Med. 336(3), 153-162 (1997).
37. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339(19), 1349-1357 (1998).
38. No authors listed. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Ital. Heart J. 1(12), 810-820 (2000).
39. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22 (2002).
40. Athyros VG, Mikhailidis DP, Papageorgiou AA et al.; GREACE collaborative group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr. Med. Res. Opin. 20(5), 627-637 (2004).
41. Serruys PW, De Feyter PJ, Benghozi R, Hugenholtz PG, Lesaffre E. The Lescol Intervention Prevention Study (LIPS): a doubleblind, placebo-controlled, randomized trial of the longterm effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int. J. Cardiovasc. Intervent. 4(4), 165-172 (2001).
42. Larosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425-1435 (2005).
43. Pedersen TR, Faergeman O, Kastelein JJP et al. High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - the IDEAL study: a randomized controlled trial. JAMA 294(19), 2437-12434 (2005).
44. MacMahon M, Kirkpatrick C, Cummings CE et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. 10, 195-203 (2000).
45. Cholesterol Treatment Trialists. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
46. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245-1255 (1986).
47. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223, 405-418 (1988).
48. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50 anniversary review. J. Int. Med. 258, 94-114 (2005).
49. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr. Opin. Lipidol. 17, 631-636 (2006).
50. Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361(22), 2113-2122 (2009).
51. Keech A, Simes RJ, Barter P et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849-1861 (2005).
52. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102(1), 21-27 (2000).
53. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med., 317(20), 1237-1245 (1987).
54. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341(6), 410-418 (1999).
55. Abourbih S, Filion KB, Joseph L et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am. J. Med. 122(10), 962.e1-8 (2009).
56. Tall AR. Plasma cholesteryl ester transfer protein. J. Lipid Res. 34(8), 1255-1274 (1993).
57. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23(2), 160-167 (2003).
58. Barter PJ, Caulfield M, Eriksson M et al.; ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109-2122 (2007).
59. Krishna R, Anderson MS, Bergman JA et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled Phase I studies. Lancet 370, 1907-1914 (2007).
60. Krishna R, Bergman AJ, Jin B et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin. Pharmacol. Ther. 84(6), 679-683 (2008).
61. Bloomfield D, Carlson GL, Sapre A et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am. Heart J. 157(2), 352-360.e2 (2009).
62. Stein EA, Stroes ES, Steiner G et al. Safety and tolerability of dalcetrapib. Am. J. Cardiol. 104(1), 82-91 (2009).
63. Stroes ES, Kastelein JJ, Bénardeau A et al. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br. J. Pharmacol. 158(7), 1763-1770 (2009).
64. Schwartz GG, Olsson AG, Ballantyne CM et al.; dal-OUTCOMES committees and investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. 158(6), 896-901 (2009).
65. Vasan RS, Pencina MJ, Robins SJ et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 120(24), 2414-2420 (2009).
66. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J. Clin. Invest. 116(12), 3090-3100 (2006).
67. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 298(7), 786-798 (2007).
68. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290(17), 2292-2300 (2003).
69. Tardif JC, Grégoire J, L'Allier PL et al.; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297(15), 1675-1682 (2007).
70. Meyer P, Nigam A, Marcil M, Tardif J-C. The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease. Curr. Atheroscler. Rep. 11(5), 329-333 (2009).
71. Wool GD, Vaisar T, Reardon CA, Getz GS. An ApoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J. Lipid Res. 50(9), 1889-1900 (2009).
72. Schmitz G, Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim. Biophys. Acta 1735(1), 1-19 (2005).
73. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-acid-activated receptors: targeting TGR5 and farnesoid- X-receptor in lipid and glucose disorders. Trends Pharmacol. Sci. 30(11), 570-580 (2009).
74. Masson D, Koseki M, Ishibashi M et al. Increased HDL cholesterol and ApoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler. Thromb. Vasc. Biol. 29(12), 2054-2060 (2009).
75. Ganesan A, Benning L, Golub ET et al. Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens. AIDS Res. Ther. 6, 13 (2009).
76. Franssen R, Sankatsing RR, Hassink E et al. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler. Thromb. Vasc. Biol. 29(9), 1336-1341 (2009).
77. Grover SA, Kaouache M, Joseph L, Barter P, Davignon J. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch. Intern. Med. 169(19), 1775-1780 (2009).
78. Briel M, Ferreira-Gonzalez I, You JJ et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. Br. Med. J. 338, b92 (2009).
79. Sacks FM, Bray GA, Carey VJ et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N. Eng. J. Med. 360, 859-873 (2009).
80. Frikke-Schmidt R, Nordestgaard BG, Stene MCA et al. Association of loss of function mutations in the ABCA1 gene with high-density lipoproteon cholesterol levels and risk of ischemic heart disease. JAMA 299(21), 2524-2532 (2008).
81. Fazio S, Lincton MF. Elevated high-density levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma. J. Clin. Endocrinol. Metab. 94(4), 1081-1083 (2009).
82. Alrasadi K, Awan K, Ruel I et al. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended release niacin (2 g). Am. J. Cardiol. 102, 1341-1347 (2008).